Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
92% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ENZY: No Debt )
ENZY' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ENZY's Equity to Asset is ranked higher than
94% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZY: 0.92 )
ENZY' s 10-Year Equity to Asset Range
Min: 0.67   Max: 0.92
Current: 0.92

0.67
0.92
Interest Coverage No Debt
ENZY's Interest Coverage is ranked higher than
94% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
ENZY' s 10-Year Interest Coverage Range
Min: 8.09   Max: 19.76
Current: No Debt

8.09
19.76
Z-Score: 10.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 18.10
ENZY's Operating margin (%) is ranked higher than
92% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. ENZY: 18.10 )
ENZY' s 10-Year Operating margin (%) Range
Min: -1.51   Max: 18.1
Current: 18.1

-1.51
18.1
Net-margin (%) 18.51
ENZY's Net-margin (%) is ranked higher than
93% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. ENZY: 18.51 )
ENZY' s 10-Year Net-margin (%) Range
Min: -3.75   Max: 17.54
Current: 18.51

-3.75
17.54
ROE (%) 9.35
ENZY's ROE (%) is ranked higher than
91% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. ENZY: 9.35 )
ENZY' s 10-Year ROE (%) Range
Min: 14.99   Max: 15.5
Current: 9.35

14.99
15.5
ROA (%) 8.15
ENZY's ROA (%) is ranked higher than
93% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ENZY: 8.15 )
ENZY' s 10-Year ROA (%) Range
Min: 9.9   Max: 12.16
Current: 8.15

9.9
12.16
ROC (Joel Greenblatt) (%) 20.01
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. ENZY: 20.01 )
ENZY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 27.97   Max: 28.7
Current: 20.01

27.97
28.7
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ENZY Guru Trades in Q4 2013

John Paulson 1,733,030 sh (New)
» More
Q1 2014

ENZY Guru Trades in Q1 2014

John Paulson 4,271,230 sh (New)
John Paulson Sold Out
» More
Q2 2014

ENZY Guru Trades in Q2 2014

John Paulson 4,271,230 sh (unchged)
» More
Q3 2014

ENZY Guru Trades in Q3 2014

John Paulson 4,271,230 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-03-31 Sold Out 0.23%$21.52 - $29.5 $ 8.2-69%0
John Paulson 2013-12-31 New Buy0.23%$16.555 - $33.44 $ 8.2-66%1733030
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.80
ENZY's P/E(ttm) is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZY: 18.80 )
ENZY' s 10-Year P/E(ttm) Range
Min: 15.05   Max: 65.06
Current: 18.8

15.05
65.06
P/B 1.50
ENZY's P/B is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. ENZY: 1.50 )
ENZY' s 10-Year P/B Range
Min: 1.2   Max: 11
Current: 1.5

1.2
11
P/S 3.60
ENZY's P/S is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. ENZY: 3.60 )
ENZY' s 10-Year P/S Range
Min: 1.17   Max: 3.57
Current: 3.6

1.17
3.57
EV-to-EBIT 14.57
ENZY's EV-to-EBIT is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZY: 14.57 )
ENZY' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 61.8
Current: 14.57

7.2
61.8
Current Ratio 7.02
ENZY's Current Ratio is ranked higher than
81% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ENZY: 7.02 )
ENZY' s 10-Year Current Ratio Range
Min: 2.31   Max: 8.76
Current: 7.02

2.31
8.76
Quick Ratio 4.76
ENZY's Quick Ratio is ranked higher than
74% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. ENZY: 4.76 )
ENZY' s 10-Year Quick Ratio Range
Min: 1.5   Max: 7.31
Current: 4.76

1.5
7.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.91
ENZY's Price/Net Cash is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. ENZY: 9.91 )
ENZY' s 10-Year Price/Net Cash Range
Min: 5.8   Max: 10.39
Current: 9.91

5.8
10.39
Price/Net Current Asset Value 4.47
ENZY's Price/Net Current Asset Value is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. ENZY: 4.47 )
ENZY' s 10-Year Price/Net Current Asset Value Range
Min: 3.85   Max: 28.53
Current: 4.47

3.85
28.53
Price/Tangible Book 1.51
ENZY's Price/Tangible Book is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. ENZY: 1.51 )
ENZY' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 6.81
Current: 1.51

1.3
6.81
Price/Median PS Value 1.47
ENZY's Price/Median PS Value is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ENZY: 1.47 )
ENZY' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.27
Current: 1.47

0.49
1.27
Price/Graham Number 1.11
ENZY's Price/Graham Number is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZY: 1.11 )
ENZY' s 10-Year Price/Graham Number Range
Min: 0.96   Max: 3.35
Current: 1.11

0.96
3.35
Earnings Yield (Greenblatt) 6.80
ENZY's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. ENZY: 6.80 )
ENZY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 13.9
Current: 6.8

1.6
13.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:EZ4.Germany
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
ENZYMOTEC 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General a Oct 31 2014 
Kessler Topaz Meltzer & Check, LLP Reminds Enzymotec Ltd. (ENZY) Shareholders of Class Action Lawsui Oct 15 2014 
Saxena White P.A. Files Securities Fraud Class Action Against Enzymotec Ltd. Oct 15 2014 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% Nov 18 2014
2014-11-17 Fredrik Lindberg appointed CEO of Enzymatica Nov 17 2014
Enzymotec Ltd Earnings Call scheduled for 8:30 am ET today Nov 13 2014
Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results Nov 13 2014
Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results Nov 13 2014
Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD Nov 11 2014
2014-10-13 Enzymatica AB: Launch in Denmark expands ColdZyme® to all of Scandinavia Nov 05 2014
ENZYMOTEC 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General... Oct 31 2014
Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results Oct 30 2014
Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results Oct 30 2014
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving... Oct 29 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Oct 29 2014
NOV. 4th DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd.... Oct 27 2014
Which Stocks Hurt Billionaire Portfolios the Most in 2014? Oct 27 2014
ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Oct 25 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd.... Oct 21 2014
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action... Oct 16 2014
Kessler Topaz Meltzer & Check, LLP Reminds Enzymotec Ltd. (ENZY) Shareholders of Class Action... Oct 08 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd.... Oct 06 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Oct 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK